ÐÔÃü¿ÆÑ§Ñ§ÔºÕÅÖÒ»Ô½ÌÊÚ¿ÎÌâ×éÔÚHaematologicaÔÓÖ¾°ä·¢×êÑÐÂÛÎÄ

°ä²¼¹¦·ò£º2023-09-08Ͷ¸å£ºÑîÒÐÌì ²¿ÃÅ£ºÐÔÃü¿ÆÑ§Ñ§Ôº ä¯ÀÀ´ÎÊý£º

½üÈÕ £¬CA88ÐÔÃü¿ÆÑ§Ñ§ÔºÕÅÖÒ»Ô½ÌÊÚ¿ÎÌâ×éÔÚ°×Ѫ²¡¸Éϸ°û×ÔÎÒ¸üлúÀíµÄµ÷¿Ø×êÑÐÖлñµÃ×îнøÕ¹£º·¢ÏÖ¸ßЧ±í°×miR-30e-5p¿ÉÔÚÓ×ÊóÌåÄÚÓÐЧÒÖÔì°×Ѫ²¡¸Éϸ°ûµÄ³É³¤ £¬µ¢¸éËèϵ°×Ѫ²¡Ä£ÐÍÓ×ÊóµÄÉú¼Æ¹¦·ò £¬²¢Ã÷È·Æä¾ßÌå·Ö×Ó×÷ÓûúÔì¡£ÓйØ×êÑгɾÍÔÚ¹ú¼ÊѪҺ²¡Àí¼°ÉúÀíѧÆÚ¿¯¡¶Haematologica¡·Éϰ䷢ÌâΪ¡°miR-30e-5p regulates leukemia stem cell self-renewal through the Cyb561/ROS signaling pathway¡±µÄ×êÑÐÂÛÎÄ£¨ÂÛÎÄÁ´½Ó£ºhttps://haematologica.org/article/view/haematol.2023.282837£©¡£¸ÃÔÓÖ¾µÄ×îÐÂÓ°ÏìÒò×ÓΪ10.1¡£¸Ã×êÑгɾÍÊÇÓÉCA88Ó뻪ÖпƼ¼´óѧͬ¼ÃҽѧԺ¡¢ÖÐÄÏ´óÑ§ÏæÑŶþÔº¼°ÃÀ¹úÒÁÀûŵÒÁ´óѧ֥¼Ó¸ç·ÖУµÈ¹úÄÚ±í¶à¼Ò¿ÆÑлú¹¹ºÏ×÷ £¬CA88ÕÅÖÒ»Ô½ÌÊÚΪ¹²Í¬Í¨Ñ¶×÷Õß £¬ÐÔÃüѧԺ˶ʿ×êÑÐÉú¸ðÑÔÎÄΪÂÛÎĵÚÒ»×÷Õß £¬CA88ΪµÚһʵÏÖµ¥Ôª¡£

B1E100B34B3CC6A91424117DC0A_F55C754F_BAA2

¼±ÐÔËèϵ°×Ѫ²¡£¨Acute myeloid leukemia, AML£©ÊÇÒ»ÀàÔìѪϵͳµÄ¶ñÐÔÖ×Áö¼²²¡ £¬ÖØÒªÊÇÓÉÓÚÔìѪ¸É×æÏ¸°ûÖеÄijЩ»ùÒò²úÉúÍ»±ä»ò»ùÒò×é³ÁÅŶø²úÉúµÄ°×Ѫ²¡¸Éϸ°ûËùÖ¡£¹ÌÈ»½üÄêÀ´¶ÔAMLÒ½ÖÎˮƽÒÑÓп϶¨Ë®Æ½µÄÌá¸ß £¬µ«³ÉÈËAMLµÄ5ÄêÎÞ²¡Éú¼ÆÂʽöԼΪ24%¡£Òò¶ø £¬×êÑа×Ѫ²¡¸Éϸ°û×ÔÎÒ¸üеķÖ×Ó»úÀí¶ÔAMLµÄÁÙ´²Ò½ÖÎÏÔµÃÓÈΪ³ÁÒªºÍ»ð¼±¡£¶àÏî×êÑÐÅú×¢ £¬°×Ѫ²¡¸Éϸ°ûµÄ×ÔÎÒ¸üÐÂÄÜÁ¦¿ÉÏÔÖøÓ°ÏìAMLµÄ²úÉú·¢Õ¹¡£Í¬Ê± £¬ÓÉÓÚÕý³£ÔìѪ¸Éϸ°ûºÍ°×Ѫ²¡¸Éϸ°ûÔÚ×ÔÎÒ¸üÐÂÄÜÁ¦Éϵĵ÷¿ØÓµÓÐÖî¶àÀàËÆÐÔ £¬Òò¶ø°×Ѫ²¡¸Éϸ°ûͨ³£ÄÑÒÔÓÃͨÀý¼¿Á©»¯ÁƼ¿Á©½øÐиù³ý¡£¸ÃÂÛÎÄÔÚǰÆÚ×êÑлù´¡ÉÏ £¬·¢ÏÖmiR-30e-5pÔÚ²»Ó°ÏìÕý³£ÔìѪ¸Éϸ°ûÉúÀíÖ°ÄܵÄǰÌáÏ £¬¿ÉÏÔÖøÒÖÔì°×Ѫ²¡¸Éϸ°ûµÄ²úÉú·¢Õ¹ £¬µ¢¸é°×Ѫ²¡Ä£ÐÍÓ×ÊóµÄÉú¼Æ¹¦·ò¡£Í¨¹ýÉúÎïÐÅϢѧµÈ¶àÖÖ¼¼Êõ¼¿Á© £¬×êÑз¢ÏÖ£ºÔÚ°×Ѫ²¡¸Éϸ°ûÖÐmiR-30e-5pÊÇͨ¹ýµ÷¿ØÏÂÓΰзÖ×ÓCyb561 £¬Ó°Ïì°×Ѫ²¡¸Éϸ°ûÄÚ¿¹»µÑªËá¼°¹Èë׸ÊëĵÄˮƽ½ø¶øµ÷¿Ø°ûÄÚROS £¬×îÖÕ¶Ô°×Ѫ²¡¸Éϸ°ûµÄϸ°ûÖÜÆÚºÍϸ°ûµòÍö²úÉú³ÁÒªµ÷½Ú×÷Óá£

5157DB1368B7EE335CFE1E2ADBE_07CDB557_4646

¸Ã×êÑй¤×÷µÃµ½Á˹ú¶ÈÌìÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢ÉϺ£ÊпÆÎ¯ÃæÉÏÏîÄ¿¡¢ÉϺ£ÊнÌί¡°¶«·½Ñ§Õß¡±´òËã¼°¸ú×Ù´òËãµÈÔÞÖúºÍÖ§³Ö¡£

¡¾ÍøÕ¾µØÍ¼¡¿